Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Fludrocortisone Sudden Sensorineural Hearing Loss Study

Also known as: Fludrocortisone, Mineralocorticoid treatment for sudden hearing loss

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 1

Status

Discontinued

Target Gene

—

Route / Mode

Oral

Confidence

72%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, sudden-hearing-loss, study-level

Trial IDs

Mechanism

Terminated academic early Phase 1 study of oral mineralocorticoid therapy for sudden sensorineural hearing loss after incomplete recovery with standard glucocorticoid treatment.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

The registry verifies a terminated Oregon Health and Science University early Phase 1 fludrocortisone study. It should be treated as a historical academic generic-drug study rather than a live commercial hearing-loss pipeline program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT01186185

Open

Key Events

2012-08-01

Registry-listed start of fludrocortisone sudden hearing loss study

2016-03-01

Registry-listed actual completion for terminated study

Clinical Trials (1)